Skip NavigationSkip to Content

NCI at Frederick Scientific Publications Advanced Search

Search

  1. NCI-F Publications

  2. Return to Quick Search
Search
  2. Year Published:

Your search returned 28 results.
User Information
Export Records
  1. 1.   Bioinformatic analysis linking genomic defects to chemosensitivity and mechanism of action
  2. Covell,David
  3. PloS one. 2021, Apr 28; 16(4):
  1. 2.   A YAP/FOXM1 axis mediates EMT-associated EGFR inhibitor resistance and increased expression of spindle assembly checkpoint components
  2. Nilsson, Monique B.; Sun, Huiying; Robichaux, Jacqulyne; Pfeifer, Matthias; McDermott, Ultan; Travers, Jon; Diao, Lixia; Xi, Yuanxin; Tong, Pan; Shen, Li; Hofstad, Mia; Kawakami, Masanori; Le, Xiuning; Liu, Xi; Fan, Youhong; Poteete, Alissa; Hu, Limei; Negrao, Marcelo; Tran, Hai; Dmitrovsky, Ethan; Peng, David; Gibbons, Don L.; Wang, Jing; Heymach, John
  3. SCIENCE TRANSLATIONAL MEDICINE. 2020, SEP 2; 12(559): pii: aaz4589.
  1. 3.   Review: Precision medicine and driver mutations: Computational methods, functional assays and conformational principles for interpreting cancer drivers
  2. Nussinov,Ruth; Jang,Hyunbum; Tsai,Chung-Jung; Cheng, Feixiong
  3. PLoS computational biology. 2019, Mar; 15(3):
  1. 4.   Personal Mutanomes Meet Modern Oncology Drug Discovery and Precision Health
  2. Cheng, Feixiong; Liang, Han; Butte, Atul J.; Eng, Charis; Nussinov, Ruth
  3. Pharmacological reviews. 2019, Jan; 71(1): 1-19.
  1. 5.   Multiple configurations of EGFR exon 20 resistance mutations after first- and third-generation EGFR TKI treatment affect treatment options in NSCLC
  2. Goldberg, Michael E.; Montesion, Meagan; Young, Lauren; Suh, James; Greenbowe, Joel; Kennedy, Mark; Giaccone, Giuseppe; Akerley, Wallace L.; Dowlati, Afshin; Creelan, Benjamin C.; Hicks, James K.; Hesketh, Paul J.; Kelly, Karen L.; Riess, Jonathan W.; Miller, Vincent A.; Stephens, Philip J.; Frampton, Garrett M.; Ali, Siraj; Gregg, Jeffrey P.; Albacker, Lee A.
  3. PLOS ONE. 2018, NOV 27; 13(11):
  1. 6.   LMTK3 confers chemo-resistance in breast cancer
  2. Stebbing, Justin; Shah, Kalpit; Lit, Lei Cheng; Gagliano, Teresa; Ditsiou, Angeliki; Wang, Tingting; Wendler, Franz; Simon, Thomas; Szabo, Krisztina Sara; O'Hanlon, Tim; Dean, Michael; Roslani, April Camilla; Cheah, Swee Hung; Lee, Soo-Chin; Giamas, Georgios
  3. ONCOGENE. 2018, JUN; 37(23): 3113-3130.
  1. 7.   Engaging Anaphase Catastrophe Mechanisms to Eradicate Aneuploid Cancers
  2. Kawakami, Masanori; Mustachio, Lisa Maria; Liu, Xi; Dmitrovsky, Ethan
  3. Molecular Cancer Therapeutics. 2018, Apr; 17(4): 724-731.
  1. 8.   Phase I Trial of M7824 (MSB0011359C), a Bifunctional Fusion Protein Targeting PD-L1 and TGF beta, in Advanced Solid Tumors
  2. Strauss, Julius; Heery, Christopher R.; Schlom, Jeffrey; Madan, Ravi A.; Cao, Liang; Kang, Zhigang; Lamping, Elizabeth; Marte, Jennifer L.; Donahue, Renee N.; Grenga, Italia; Cordes, Lisa; Christensen, Olaf; Mahnke, Lisa; Helwig, Christoph; Gulley, James L.
  3. Clinical Cancer Research. 2018, Mar 15; 24(6): 1287-1295.
  1. 9.   Complexity in the signaling network: insights from the use of targeted inhibitors in cancer therapy
  2. Logue, J. S.; Morrison, D. K.
  3. Genes & Development. 2012, Apr; 26(7): 641-650.
  1. 10.   Preclinical therapeutic response of residual metastatic disease is distinct from its primary tumor of origin
  2. Day, C. P.; Carter, J.; Bonomi, C.; Hollingshead, M.; Merlino, G.
  3. International Journal of Cancer. 2012, Jan; 130(1): 190-199.
  1. 11.   Supplementation with alpha-Tocopherol or beta-Carotene Reduces Serum Concentrations of Vascular Endothelial Growth Factor-D, but Not -A or -C, in Male Smokers
  2. Mondu, A. M.; Rager, H. C.; Kopp, W.; Virtamo, J.; Albanes, D.
  3. Journal of Nutrition. 2011, Nov; 141(11): 2030-2034.
  1. 12.   Activation of the c-Jun N-terminal Kinase/Activating Transcription Factor 3 (ATF3) Pathway Characterizes Effective Arylated Diazeniumdiolate-Based Nitric Oxide-Releasing Anticancer Prodrugs
  2. Maciag, A. E.; Nandurdikar, R. S.; Hong, S. Y.; Chakrapan, H.; Diwan, B.; Morris, N. L.; Shami, P. J.; Shiao, Y. H.; Anderson, L. M.; Keefer, L. K.; Saavedra, J. E.
  3. Journal of Medicinal Chemistry. 2011, Nov; 54(22): 7751-7758.
  1. 13.   Synthesis and Biological Activities of (R)- and (S)-N-(4-Methoxyphenyl)-N,2,6-trimethyl-6,7-dihydro-5H-cyclopenta[d]pyri midin-4-aminium Chloride as Potent Cytotoxic Antitubulin Agents
  2. Ganglee, A.; Zhao, Y.; Hamel, E.; Westbrook, C.; Mooberry, S. L.
  3. Journal of Medicinal Chemistry. 2011, Sep; 54(17): 6151-6155.
  1. 14.   Methotrexate induces apoptosis through p53/p21-dependent pathway and increases E-cadherin expression through downregulation of HDAC/EZH2
  2. Huang, W. Y.; Yang, P. M.; Chang, Y. F.; Marquez, V. E.; Chen, C. C.
  3. Biochemical Pharmacology. 2011, Feb; 81(4): 510-517.
  1. 15.   Synthesis and Discovery of Water-Soluble Microtubule Targeting Agents that Bind to the Colchicine Site on Tubulin and Circumvent Pgp Mediated Resistance
  2. Gangjee, A.; Zhao, Y.; Lin, L.; Raghavan, S.; Roberts, E. G.; Risinger, A. L.; Hamel, E.; Mooberry, S. L.
  3. Journal of Medicinal Chemistry. 2010, Nov; 53(22): 8116-8128.
  1. 16.   The molecular pathology of cancer
  2. Harris, T. J. R.; McCormick, F.
  3. Nature Reviews Clinical Oncology. 2010, May; 7(5): 251-265.
  1. 17.   Biological Assessment of Triazine Dendrimer: Toxicological Profiles, Solution Behavior, Biodistribution, Drug Release and Efficacy in a PEGylated, Paclitaxel Construct
  2. Lo, S. T.; Stern, S.; Clogston, J. D.; Zheng, J. W.; Adiseshaiah, P. P.; Dobrovolskaia, M.; Lim, J. D.; Patri, A. K.; Sun, X. K.; Simanek, E. E.
  3. Molecular Pharmaceutics. 2010, Jul-Aug; 7(4): 993-1006.
  1. 18.   Advantage of combining NLCQ-1 (NSC 709257) with radiation in treatment of human head and neck xenografts
  2. Papadopoulou, M. V.; Bloomer, W. D.; Taylor, A. P.; Hernandez, M.; Blumenthal, R. D.; Hollingshead, M. G.
  3. Radiation Research. 2007, Jul; 168(1): 65-71.
  1. 19.   Identification of the genes for kidney cancer: Opportunity for disease-specific targeted therapeutics
  2. Linehan, W. M.; Pinto, P. A.; Srinivasan, R.; Merino, M.; Choyke, P.; Choyke, L.; Coleman, J.; Toro, J.; Glenn, G.; Vocke, C.; Zbar, B.; Schmidt, L. S.; Bottaro, D.; Neckers, L.
  3. Clinical Cancer Research. 2007, Jan; 13(2): 671S-679S.
  1. 20.   Functional studies of the chromosome 3p21.3 candidate tumor suppressor gene BLU/ZMYND10 in nasopharyngeal carcinoma
  2. Yau, W. L.; Lung, H. L.; Zabarovsky, E. R.; Lerman, M. I.; Sham, J. S. T.; Chua, D. T. T.; Tsao, S. W.; Stanbridge, E. J.; Lung, M. L.
  3. International Journal of Cancer. 2006, Dec; 119(12): 2821-2826.
  1. 21.   Analysis of a new homozygous deletion in the tumor suppressor region at 3p12.3 reveals two novel intronic noncoding RNA genes
  2. Angeloni, D.; ter Elst, A.; Wei, M. H.; van der Veen, A. Y.; Braga, E. A.; Klimov, E. A.; Timmer, T.; Korobeinikova, L.; Lerman, M. I.; Buys, C.
  3. Genes Chromosomes & Cancer. 2006, Jul; 45(7): 676-691.
  1. 22.   STRA13 expression and subcellular localisation in normal and tumour tissues: implications for use as a diagnostic and differentiation marker
  2. Ivanova, A.; Liao, S. Y.; Lerman, M. I.; Ivanov, S.; Stanbridge, E. J.
  3. Journal of Medical Genetics. 2005, JUL; 42(7): 565-576.
  1. 23.   NLCQ-1 (NSC 709257) in combination with radiation against human glioma U251 xenografts
  2. Papadopoulou, M. V.; Bloomer, W. D.; Hollingshead, M. G.
  3. Anticancer Research. 2005, MAY-JUN; 25(3B): 1865-1869.
  1. 24.   Small molecule toxins targeting tumor receptors
  2. Dyba, M.; Tarasova, N. I.; Michejda, C. J.
  3. Current Pharmaceutical Design. 2004 10(19): 2311-2334.
  1. 25.   Therapeutic advantage from combining paclitaxel with the hypoxia-selective cytotoxin NLCQ-1 in murine tumor- or human xenograft-bearing mice
  2. Papadopoulou, M. V.; Ji, M.; Ji, X. H.; Bloomer, W. D.; Hollingshead, M. G.
  3. Cancer Chemotherapy and Pharmacology. 2002 50(6): 501-508.
NCI at Frederick

You are leaving a government website.

This external link provides additional information that is consistent with the intended purpose of this site. The government cannot attest to the accuracy of a non-federal site.

Linking to a non-federal site does not constitute an endorsement by this institution or any of its employees of the sponsors or the information and products presented on the site. You will be subject to the destination site's privacy policy when you follow the link.

ContinueCancel